Press Releases

GlobeNewswire, Inc.

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Meridian Corporation (“Meridian” or the “Company”) (NASDAQ: MRBK). Such investors are advised to contact Danielle Peyton at...

GlobeNewswire, Inc.

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of JetBlue Airways Corporation (“JetBlue” or the “Company”) (NASDAQ: JBLU). Such investors are advised to contact Danielle Peyton at...

GlobeNewswire, Inc.

GUELPH, Ontario, May 12, 2026 (GLOBE NEWSWIRE) -- Linamar Corporation (TSX:LNR) today announced detailed results of the votes cast for two motions held during the Annual General Meeting of the Company on Thursday, May 12, 2026 in Guelph, Ontario,...

GlobeNewswire, Inc.

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Primoris Services Corporation (“Primoris” or the “Company”) (NYSE: PRIM). Such investors are advised to contact Danielle Peyton at...

GlobeNewswire, Inc.

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against LKQ Corporation (“LKQ” or the “Company”) (NASDAQ: LKQ). Such investors are advised to contact Danielle Peyton at...

GlobeNewswire, Inc.

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against SES AI Corporation (“SES AI” or the “Company”) (NYSE: SES). Such investors are advised to contact Danielle Peyton at...

GlobeNewswire, Inc.

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking clinical trial presentation at major cardiology...

GlobeNewswire, Inc.

Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda Announced appointment of Chris Murphy as CFO...

GlobeNewswire, Inc.

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European...

GlobeNewswire, Inc.

Q1 Revenue of $9.0 million Q1 Income from Continuing Operations of $0.8 million Q1 Thyroid volume year-over-year increase of 10% Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) -- Interpace...

GlobeNewswire, Inc.

Proprietary robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe Synchrony digital operating room system received U.S. FDA clearance in...

GlobeNewswire, Inc.

Next anticipated Revita® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for topline 6-month randomized data from the REMAIN-1...

GlobeNewswire, Inc.

C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HCV on Track to Complete Enrollment Mid-2026;...

GlobeNewswire, Inc.

Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Timeline for submission of NDA of deucrictibant IR for the on-demand treatment of HAE attacks remains on-track in...

GlobeNewswire, Inc.

First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into 2027, including completion of...

GlobeNewswire, Inc.

Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a durable 80% CR...

GlobeNewswire, Inc.

REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported...

GlobeNewswire, Inc.

JACKSONVILLE, Fla., May 12, 2026 (GLOBE NEWSWIRE) -- CSX Corp. (NASDAQ: CSX) announced that the Company’s Board of Directors approved a $0.14 per share quarterly dividend on the Company’s common stock.

GlobeNewswire, Inc.

New York, May 12, 2026 (GLOBE NEWSWIRE) -- Inception Growth Acquisition Limited (NASDAQ: IGTA, the “Company”), a publicly traded special purpose acquisition company, announced today that on May 11, 2026, the Company deposited $12,203.33 into the...

EIN Presswire

With updates from regional leaders, economic and workforce discussions, a business expo, and recognition of outstanding local businesses and community members.